Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zhike juhong granules
- Development stage
- Phase 2
- Lead developer
- Kangzhi Pharmaceutical
- Administration
- Oral
01
Overview
Zhike Juhong Granules is a Traditional Chinese Medicine (TCM) formulation developed by Kangzhi Pharmaceutical. It is primarily indicated for the treatment of respiratory conditions characterized by the TCM pattern of phlegm-heat obstructing the lung. The drug is currently in Phase II clinical development in China for the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). The formulation typically aims to clear lung heat, resolve phlegm, and alleviate cough through a blend of botanical extracts known for their antitussive and expectorant properties.
- Other names
- 止咳橘红颗粒Zhike Juhong Keli
Beyond the preview
Go deeper on zhike juhong granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zhike juhong granules.